Navigation Links
Interleukin Genetics Announces Strategic Divestment of Alan James Group
Date:7/2/2009

WALTHAM, Mass., July 2 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that on June 30, 2009 it executed an agreement to sell the Alan James Group assets of its subsidiary AJG Brands, Inc. to Pep Products, Inc., a subsidiary of Nutraceutical Corporation, for approximately $4.6 million in cash. The transaction was completed following the close of business on June 30th.

"While the Alan James Group business saw an increase in sales during the last fiscal year and we were able to introduce two new products to the market in the past seven months, this transaction allows us to focus our efforts on growing our core genetic testing business. The sale of AJG provides non-dilutive cash to continue development and promotion of our genetic testing services and products including our new brand of Inherent Health tests," said Lewis H. Bender, CEO, Interleukin Genetics.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests, including its new brand of Inherent Health genetic test products that empower consumers to maintain health and wellness, and assists pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property, and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics is headquartered in Waltham, MA. For more information please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding the Company's ability to develop genetic tests that identify genetic variations that affect risk of heart disease, periodontal disease and osteoporosis, nutritional needs and optimal weight-loss methods, to identify nutritional and lifestyle decisions that favorably affect such conditions, to provide such information in a format tailored to the individual, and to otherwise make progress in advancing the Company's core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of the Company's products, the risk of technology and product obsolescence, delays in product development, the performance of commercial partners, the availability of adequate capital, the actions of competitors and other competitive risks, and those other risks and uncertainties described in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics Launches Inherent Health Brand of Genetic Tests Offering Clear and Personalized Insights to Wellness
2. Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting
3. Interleukin Genetics Reports First Quarter 2009 Financial Results
4. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
5. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
6. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
7. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
8. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
9. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
10. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
11. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology: